- 1 Digital health app data reveals an effect of ovarian hormones on long COVID and myalgic
- 2 encephalomyelitis symptoms
- 3

6

- 4 **Authors:** Abigail Goodship MRes<sup>1</sup>, Rory Preston MSc<sup>2</sup>, Dr. Joseph T Hicks PhD<sup>3</sup>, Harry Leeming
- 5 MEng<sup>2</sup>, Christian Morgenstern MSci<sup>3</sup>, Dr. Victoria Male PhD<sup>1</sup>
- Department of Metabolism, Digestion and Reproduction, Imperial College London, Chelsea
   and Westminster Campus, London SW10 9NH
- 9 2. Visible Health Inc., 251 Little Falls Dr., Wilmington DE, USA
- 10 3. MRC Centre for Global Infectious Disease Analysis, Jameel Institute, School of Public Health,
- 11 Imperial College London, London, W12 7TA, UK
- 12

- 14 **Telephone:** 020 3315 800
- 15 Email: v.male@imperial.ac.uk
- 16

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

<sup>13</sup> Corresponding author: Dr. Victoria Male PhD<sup>1</sup>

# 17 Summary

# 18 Background

- 19 Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) disproportionately
- 20 affect females, suggesting modulation by sex hormones. We sought to investigate whether symptom
- 21 severity is influenced by changes in sex hormones over the menstrual cycle, or by hormonal
- 22 contraception.

# 23 Methods

- 24 We carried out a retrospective analysis of menstrual and symptom data, prospectively collected via
- 25 the Visible app from individuals with long COVID, ME/CFS, or both, who had regular menstrual
- 26 cycles, between 7th September 2022 and 6th March 2024. Mixed-effects models were used to
- 27 examine associations between symptom severity, menstrual cycle phase and contraception type.

# 28 Findings

29 948 users were included; 100% of users were female and 92.6% identified as women. The most tracked 30 symptoms were fatigue (99.5% of users), brain fog (88.3%), headaches (85.1%) and muscle aches 31 (78.6%). All menstrual cycle phases showed a modest, but significant, improvement compared to the 32 menstrual phase, most markedly the early luteal (IRR = 0.963, 95% CI: 0.958-0.968), but also the 33 follicular (IRR = 0.985, 95% CI: 0.981-0.990) and late luteal phases (IRR = 0.980, 95% CI: 0.974-34 0.985). Crashes (sudden and severe worsening of symptoms following exertion) were significantly more 35 frequent during menstruation than in other phases. Users of combined hormonal contraception (n=70) 36 had a statistically significant reduction in overall symptom score (OR = 0.827, 95% CI: 0.690-0.992) 37 and crash incidence (OR = 0.548, 95% CI: 0.350-0.856) compared to those not using contraception 38 (n=786).

# 39 Interpretation

- 40 Menstruation is associated with worsened symptoms in long COVID and ME/CFS. Users of combined
- 41 hormonal contraception report a lower symptom burden than non-users, suggesting a modulatory role
- 42 of ovarian hormones. These findings could empower menstruating people living with long COVID and
- 43 ME/CFS to anticipate cyclical changes in symptoms and plan their activities accordingly, and could
- 44 also inform their use of contraception.

# 45 Funding

- 46 UK Medical Research Council, NIHR, Community Jameel, the Eric and Wendy Schmidt Fund for
- 47 Strategic Innovation, Bill & Melinda Gates Foundation, Borne, Action Medical Research, and Genesis
- 48 Research Trust.
- 49

#### 50 Introduction

- 51 Four years after the first identification of novel coronavirus SARS-CoV-2, the spread of coronavirus 52 disease 2019 (COVID-19) continues to profoundly impact people's lives. Whilst most SARS-CoV-2 53 infections resolve within 4 weeks, over 10% progress to a chronic multisystemic condition known as 54 'long COVID'.<sup>1</sup> The Winter COVID-19 Infection study, conducted between November 2023 and March 55 2024, estimated that 2 million people currently live with long COVID in the UK.<sup>2</sup> Of those who reported 56 having long COVID, 71.1% reported having long COVID for over a year, 51.3% over 2 years and 30.6% 57 over 3 years.<sup>2</sup> Long COVID symptoms are wide-ranging, but commonly include fatigue, brain fog, 58 shortness of breath, insomnia and post-exertional malaise.<sup>3</sup> and can significantly reduce guality of life.<sup>4</sup>
- 59 A substantial fraction of long COVID cases also meet the diagnostic criteria for myalgic 60 encephalomyelitis (ME), also known as chronic fatigue syndrome (CFS).<sup>5-8</sup> Whilst not all cases of
- 61 ME/CFS have an identifiable infectious trigger, many are preceded by a viral infection such as glandular
- 62 fever,<sup>9</sup> or Ross River virus.<sup>10</sup> The prevalence of ME/CFS is estimated to be between 0.59% and 1.3%,<sup>11-</sup>
- <sup>13</sup> and around a guarter of people living with with ME/CFS are housebound. <sup>14</sup> Despite the profound 63
- impact ME/CFS can have on quality of life, research has been consistently underfunded.<sup>15</sup> Given the 64
- 65 historic neglect of ME/CFS and the recent emergence of long COVID, as well as the complexity of both
- 66 diseases, many questions about their pathophysiology remain unanswered.
- Long COVID and ME/CFS both affect approximately twice as many females as males<sup>16,17</sup> and higher 67 oestrogen may be beneficial in females with acute COVID-19.<sup>18,19</sup> Whilst the pathophysiology of long 68 69 COVID and ME/CFS are still unclear, a dysregulated immune response may play a role, with the 70 discovery of autoantibodies in long COVID patients supporting the suggestion that long COVID could 71 be an autoimmune disease. <sup>6,20</sup> Sex hormones (oestrogen, progesterone and testosterone) modulate 72 sex differences in immune function<sup>21</sup> and phases of the menstrual cycle correlate with symptoms of 73 chronic, and particularly autoimmune, conditions,<sup>22</sup> summarised in Figure 1. Symptoms of rheumatoid 74 arthritis, inflammatory bowel disease, lupus, multiple sclerosis and asthma all worsen at or shortly 75 before menstruation.<sup>22</sup> Hormonal contraception alters the cyclical fluctuations in ovarian hormones 76 across the menstrual cycle and has an association with altered disease susceptibility and severity, <sup>22</sup> 77 with users experiencing improved symptoms of multiple sclerosis.<sup>23</sup>
- 78 Cross-sectional surveys have suggested that long COVID symptoms may also vary with the
- 79 menstrual cycle,<sup>3,24</sup> but these approaches can be affected by recruitment and recall bias. Many
- 80 individuals track both menstrual cycles and disease symptoms using apps, entering data in real-time
- 81 as part of their healthcare routine. Data collected in this way are less likely to be affected by
- recruitment bias than other methods of data collection.<sup>25</sup> Visible is an app designed for people with 82
- 83 chronic health conditions (such as long COVID and ME/CFS) to track aspects of their health including
- symptoms, biometric measurements and other factors such as menstruation.<sup>26</sup> In this study, we used 84
- 85 data from the Visible app to test two hypotheses: 1) Long COVID and ME/CFS symptoms are worse
- 86 during the menstrual and premenstrual phases, improving in the mid-luteal phase, and 2) stabilising
- 87 ovarian hormone levels with hormonal contraception is associated with improved symptoms.

#### 88 **Research in context**

89

# 90 Evidence before this study

91 In acute COVID-19, there is evidence to suggest that oestrogen may have a protective effect. A 92 Swedish cohort study of post-menopausal women infected with SARS-CoV-2 (Sund et al., 2022) 93 found that women with high oestrogen had a lower risk of death compared to controls and women 94 with low oestrogen had higher risk of death compared to controls. Furthermore, a population-based 95 matched cohort study of UK women found that users of the combined hormonal contraceptive pill 96 (n=295,689) had lower rates of COVID-19 and a reduction in hospital attendance (Costeira et al., 97 2021). To our knowledge, the impact of the menstrual cycle on ME/CFS symptoms had yet to be 98 investigated prior to this study and research into long COVID and the menstrual cycle to date has 99 been limited. Arguably one of the most influential studies in the general field of long COVID is from 100 Davis et al. 2021 who reported the results of a large international patient-led survey. In addition to 101 characterising symptom prevalence. Davis et al., found that a third of menstruating participants (n =1792) reported relapses of their long COVID symptoms immediately before or during their period. In 102 103 a smaller UK survey (Newson et al., 2021, n = 460), 62% of female respondents with long COVID 104 reported that their symptoms of long COVID were worse on the days before their period. However, the 105 participant demographics were not reported, so it is unclear whether this is a representative sample.

# 106 Added value of this study

This study is the first to describe changes to long COVID and ME/CFS symptoms across the
menstrual cycle, using prospectively collected app data. Symptoms tended to be worse during the
menstrual phase and less severe during the early luteal phase, in line with our hypothesis and with
previous findings. This study is also the first to investigate the effect of hormonal contraception on
symptoms of long COVID and ME/CFS. Use of combined hormonal contraception was associated
with significantly ameliorated symptoms and a reduced risk of crashes.

# 114 Implications of all the available evidence

The finding that long COVID and ME/CFS symptoms follow a cyclical pattern over the menstrual cycle
not only gives us new insights into the role of sex hormones in these diseases but could also
empower menstruating patients to schedule more strenuous activities during phases of the cycle
when they are likely to have milder symptoms, and be less vulnerable to crashes (sudden and severe
worsening of symptoms following exertion). The finding that combined hormonal contraceptives as
associated with reduced symptoms could also inform the use of contraception in people living with
long COVID and ME/CFS.

122

# 123 Methods

# 124 Data source and collection

125 A retrospective analysis of symptom severity and menstrual cycle phase was conducted on 126 prospectively collected data from users of the Visible app.<sup>26</sup> On registration, users enter their birth year, 127 gender and whether they consider themselves to have long COVID, ME/CFS or another condition. After 128 consenting to participate, users were asked to complete a survey on their use of hormonal 129 contraception, pregnancy status, breastfeeding status, number of pregnancies, and number of births. 130 Each day, users were prompted to self-report their commonly experienced symptoms on a 4-point Likert 131 scale [None, Mild, Moderate, Severe] and whether they are currently experiencing a crash (appendix, 132 p23). The following definition was provided: "Crashes usually occur as a part of post-exertional 133 symptom exacerbation and affect your ability to carry out your usual activities. They normally last a few 134 days." Reports entered between 7th September 2022 to 8th March 2024 were collected.

# 135 Data cleaning and menstrual cycle phase coding

136 All data cleaning and subsequent analysis was conducted in RStudio version 2024.12.0+467.<sup>27</sup> Users 137 who did not complete the survey questions, or who were breastfeeding, pregnant or outside the age 138 range 18-45 were excluded. Under-18s were not included due to the additional ethical approval that 139 would have needed to be obtained when analysing data from children; over 45s were excluded due to 140 an increased likelihood of being perimenopausal. Any users who did not have either long COVID or 141 ME/CFS, who did not track menstrual data or who did not report a single day where they were 142 menstruating were also excluded. A menstrual cycle was counted from the first day of one menstrual 143 period to the first day of the next. The first day of a period was assigned based on the International 144 Federation of Gynecology and Obstetrics (FIGO) definition of a normal period<sup>28</sup> where the day fulfilled 145 all the following criteria: users reports being on period; user did not report being on their period the 146 previous 5 days; the following day and the day after the user either reported being on their period or did 147 not make a report; user did not report being on their period 9 and 10 days after.

148 Menstrual cycles that contained >2 consecutive days of missing menstrual tracking data or were outside of the normal length of a cycle (24-38 days, as defined by  $FIGO^{28}$ ) were removed from the dataset. 149 150 Exclusion of users and cycles is summarised in Figure 1C-D. For all remaining cycles, any missing 151 menstrual tracking data was imputed ('on period' or 'not on period') so that menstrual cycle phases 152 could be assigned. Data was imputed from the previous day with data, with the following exception: 153 missing data on the 9<sup>th</sup> or 10<sup>th</sup> day of the cycle was imputed as 'not on period', assuming duration of 154 menses does not exceed the normal 8 days.<sup>28</sup> The period end date was assigned where the day fulfilled 155 all the following criteria: user assigned as being on their period; user assigned as being on their period 156 at least the previous 2 days; user assigned as not being on their period the following day.

After defining the last day of the period, a menstrual cycle phase was assigned to each day, according to the decision tree outlined in **Figure 1E.** This follows the assumption that the follicular phase is variable, and the luteal phase consistently accounts for the final 14 days of each cycle.<sup>29</sup> The luteal

- 160 phase was further divided into the early luteal (14-8 days before the first day of period (D1), late luteal
- 161 (7-3 days before D1) and premenstrual phase (2 days before D1).
- Once menstrual cycle phases had been assigned to each day of all included cycles, any symptom and sleep tracking associated with that day were integrated into the dataset. Retrospective symptom reporting (symptom reported >2 days after date) was removed to reduce the risk of recall bias.

# 165 Descriptive statistics and statistical testing

166 Overall study population characteristics are summarised in **Table 1**. For each user, for each date, the 167 scores of each tracked symptom (all on a scale of 0-4) were summed to give an overall symptom score 168 and provide a single, comprehensive measure of a user's overall health, reflecting the cumulative 169 burden of symptoms. Incorporating the total number of symptoms experienced in addition to severity of 170 symptoms is important, as for many individuals with long COVID, navigating the volume of symptoms 171 feels overwhelming and unmanageable.<sup>30</sup> Gravidity was assessed as a binary variable (nulligravid or 172 multigravid), and the Mann-Whitney U-Test was used to test the association between gravidity and 173 mean symptom score. Kruskal-Wallis tests were used to assess the association between mean 174 symptom score and disease type, contraception type, quarters post-joining and age category. Post-hoc 175 pairwise comparisons were conducted with Dunn's tests, and p-values were adjusted using the 176 Bonferroni method to control for Type 1 error. For menstrual cycle phase, the mean of all overall 177 symptom scores across all dates in each cycle phase was calculated for each individual. The Friedman 178 test was used to compare symptom score means across phases. Post-hoc pairwise comparisons were 179 performed using the Nemenvi test. For R package details see appendix (p23). For all variables 180 described above, the mean of the mean overall symptom scores is presented as scatter plots in Figure 181 2, with pairwise significant comparisons shown on the plot (p<0.05). The percentage of days classified 182 as a crash was calculated out of the total days with data and displayed as a scatter plot with mean +/-183 standard error of the mean (SEM).

#### 185 *Mixed-effects modelling*

186 Two separate generalized linear mixed-effects models were used to evaluate the effect of relevant 187 variables on different outcomes: overall symptom score and crash occurrence. First, a negative binomial 188 regression mixed-effects model was used to investigate overall symptom score. Fixed effects included 189 menstrual phase, age category, disease type, contraception type, nulligravidity, and time since joining. 190 'Individual' was considered a random effect, which is recommended in menstrual cycle research<sup>31</sup> to 191 reliably estimate between-person differences in within-person changes across the cycle.<sup>31–33</sup> Second, 192 to evaluate the effect of the same set of variables on crash occurrence, a logistic regression (binomial 193 family with a logit link) mixed-effects model was used. Fixed effects included menstrual phase, disease 194 type, contraception type, guarters post-joining, nulligravidity and age category. 'Individual' was 195 considered a random effect, to account for within-subject variability. Details of both models can be found 196 in appendix (p24-25).

## 197 *Ethics*

All app users were given the option to consent to the use of their anonymised data for this study by


199 checking a box in the "Research" section of the Visible app. Ethical approval for this study was obtained

from the Research Governance and Integrity Team (study number 277771) at Imperial College London.

### 201 Role of the funding source

The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

medRxiv preprint doi: https://doi.org/10.1101/2025.01.24.25321092; this version posted January 27, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .



# Figure 1: Overview of the study

249 (A) A schematic representation of the menstrual cycle illustrates relative changes in pituitary and 250 ovarian hormones, follicle development, and endometrial lining. Correlated changes in disease severity 251 and infections are shown in the top panel, red indicates disease symptoms worsen/susceptibility to 252 infection increases and green indicates disease symptoms improve/response to infection improves. Created in Biorender.com.<sup>34</sup> (B) Screenshots from the Visible app illustrate how users track individual 253 disease symptoms, menstruation and crashes. Data was collected from 7th September 2022 to 6th 254 255 March 2024. (C) Flow diagram to illustrate the data cleaning process of users. Red boxes show 256 exclusions of users, blue boxes show the number of users (n) after exclusions. (D) Flow diagram to illustrate the data cleaning process of cycles after (C). Yellow boxes show cycle exclusions, turquoise 257 258 boxes show the number of cycles (n) after exclusions. (E) The decision tree for assigning menstrual 259 cycle phase to each day.

#### 261 Results

- 262 Of the 2678 users who consented for their data to be used in the study period (7<sup>th</sup> September 2022 –
- 263 6<sup>th</sup> March 2024), 948 remained after data cleaning (Figure 1C-D, Table 1). Just under half the cohort
- 264 identified as having long COVID (45.5%), around a third as having ME/CFS (34.7%) and a fifth
- 265 (19.8%) as having both long COVID and ME/CFS. Almost all users identified as women (92.6%) and
- 266 as not disabled (99.6%). The majority of users were not on hormonal contraception (82.9%), and the
- 267 remainder were split fairly evenly between oestrogen and progestin combined hormonal contraception
- 268 (combined pill (7.0%) or patch (0.4%), hereafter called "combined hormonal contraception") and
- 269 progestin-only contraceptives (intrauterine system (5.5%) or progestogen-only pill (2.3%) or
- 270 contraceptive implant (1.9%)). Around two-thirds of users had never been pregnant (65.1%) or given
- 271 birth (72.5%). The median user age was 37 (interguartile range = 10, distribution shown in appendix
- 272 (p3). There were no significant differences between the characteristics of study participants in each of
- 273 the disease groups appendix (p3).


Variable	Subgroups	Count (n)	Percentage (%)
Disease type	Long COVID	431	45·5
	ME/CFS	329	34.7
	Long COVID and ME/CFS	188	19.8
Age category	<30 years old	179	18·9
	30-39 years old	400	42.2
	≥40 years old	369	38.9
Gender	Woman	878	92.6
	Non-binary	61	6.4
	Prefer not to say	6	0.6
	Prefer to self-describe	3	0.3
Disabled	No	944	99·6
	Yes	4	0.4
Contraception type	None	786	82.9
	Combined pill	66	7.0
	Intrauterine system	52	5.5
	Progestogen-only pill	22	2.3
	Contraceptive implant	18	1.9
	Patch	4	0.4
Number of times been	0	617	65·1
pregnant	1	87	9.2
	2	132	13·9
	3	112	11.8
Number of times given	0	687	72·5
birth	1	71	7.5
	2	135	14.2
	3	55	5.8

Table 1. Demographics of study population

All variables are displayed as count (n) and percentage (%) of the total users (N = 948)

274 To determine how overall disease severity changed over the cycle and with demographic

- characteristics, we examined the daily sum of all symptom ratings, the 'symptom score', with higher
- scores indicating higher severity. For each individual, we calculated the mean symptom score across
- all relevant days. The mean symptom score was lowest in the early luteal phase, significantly higher
- in the follicular (p=0.0043) and late luteal phase (p= 0.0037) and still higher in the menstrual (p=1.5e-
- 279 08) and premenstrual phases (p= 4.6e-05) (Figure 2B). Mean symptom scores were highest in users
- with both long COVID and ME/CFS and were lowest in users with long COVID alone (**Figure 2C**).
- 281 Mean symptom scores from users with different contraception types, time since joining, gravidity and
- age categories did not significantly differ in this initial analysis (Figure 2D-G), although there was a
- 283 near significant difference (p=0.076) between users of no hormonal contraception compared to
- combined hormonal contraception (p=0.076) (Figure 2D).
- 285 On multivariable mixed-effects regression modelling, as symptom score was positively skewed and
- over-dispersed (Figure 2A), we used negative binomial regression and incorporated random
- 287 intercepts for each user. The association between menstrual cycle phase and symptom score
- remained significant adjusting for contraception type, disease type, age category, gravidity and time
- since joining the app (Table 2). Symptom scores were significantly higher during menstruation than in
- all other cycle phases. Compared to the menstrual phase, the early luteal phase showed the greatest
- reduction in symptom scores (incidence rate ratio (IRR)=0.963, p=5.77E-46); the follicular and late
- 292 Iuteal phases also showed significant reductions (IRR=0.985, p=6.49E-09 and IRR=0.980, p=4.96E-
- 293 13, respectively); and the smallest reduction was observed in the premenstrual phase (IRR=0.992,
- p=0.0425). In the regression model, symptom scores were significantly lower in users of combined
- hormonal contraception (IRR=0.872, p=0.041), in comparison to users not on hormonal
- contraception. Users on progestin-only contraception also had lower symptom scores compared to
- users not on hormonal contraception, but the difference was not significantly different (IRR=0.985,
   p=0.848). In comparison to those with long COVID, users with ME/CFS had significantly higher
- overall symptom scores (IRR=1·21, p=0·000408), and users with both long COVID and ME/CFS had
- 300 even higher overall symptom scores (IRR=1.52, p=6.11E-11). Compared to reports submitted in the
- 301 first three months since joining the app, symptom scores significantly increased over time, and by the
- 302 fifth quarter IRR = 1.06, p = 7.8E-49. This was associated with an increase in the number of
- 303 symptoms tracked over time **(appendix, p4).** Age and gravidity did not show a significant association
- 304 with symptom scores.
- 305



Age Category

310 311 Figure 2: The effects of menstrual phase, disease type, contraception type, time, gravidity and 312 age on mean symptom severity

Menstrual Phase

313 (A) Distribution of mean symptom scores is shown as a histogram, binwidth = 0.5. (B-G) Mean 314 symptom score was calculated by first summing the scores of each tracked symptom (all on a scale of 315 0-4) and secondly taking the mean across all days for each individual. Scatter plots show mean 316 symptom score split by menstrual phase (B), disease type (C), contraception type (D), quarters post-317 joining (E), gravidity (F) and age category (G). Mean symptom score is displayed as mean +/- SEM. 318 The Friedman test plus Nemenyi pairwise comparisons was used to test the significance between

319 mean symptom score and menstrual phase, due to the repeated measures nature of the data. The 320 Mann-Whitney U-Test was used to test the significance between gravidity and mean symptom score,

321 due to the binary nature of the variable. Unpaired Kruskal-Wallis tests was used to test significance 322 for all other variables, Dunn's test was used for post-hoc comparisons and p values were adjusted 323 using the Bonferroni method. P > 0.05 are considered not significant, P  $\leq$  0.05 are given 1 asterisk (\*), P  $\leq$  0.01 are given 2 asterisks (\*\*), P  $\leq$  0.001 are given 3 asterisks (\*\*\*), P  $\leq$  0.0001 are given 4 324 asterisks (\*\*\*\*). (H) Scatter plot showing mean percentage of days classified as a crash, displayed as 325 326 mean +/- SEM.

327

Table 2 The fitting	result of negative l	binomial regression	model (overall s	vmntom score)
	y result of negative i	binomia regression		ymptom score)

Fixed effe	ects	Incidence rate ratio	95% confidence interval (CI) (lower)	95% CI (upper)	P value
Menstrua	I phase				
	lenses	-	-	-	-
F	ollicular	0.985	0.981	0.990	6·49E-09
E	arly luteal	0.963	0.958	0.968	5·77E-46
L	ate luteal	0.980	0.974	0.985	4·96E-13
P	Premenstrual	0.992	0.985	1.00	0.0425*
Hormona type	l contraception				
Ν	lone	-	-	-	-
	Destrogen & progestin	0.827	0.690	0.992	0.041*
P	Progestin only	0.985	0.839	1.15	0.848
Disease t					
	ong COVID only	-	-	-	-
N	IE/CFS only	1.21	1.09	1.35	0.000408
L N	ong COVID and /IE/CFS	1.52	1.34	1.73	6·11E-11
Age cate					
	: 30	-	-	-	-
3	0-39	0.982	0.860	1.12	0.790
>	-= 40	0.913	0.789	1.06	0.223
Gravidity					
Ν	Iultigravida	-	-	-	-
Ν	lulligravida	0.911	0.815	1.02	0.0992
Quarters	post-joining				
1		-	-	-	-
2	2	1.01	1.00	1.01	0.00207*
3	6	1.01	1.00	1.02	0.000786
4		1.04	1.03	1.05	1·13E-29
5	i	1.06	1.05	1.06	7·8E-49*
6	;	1.05	1.03	1.07	4·32E-05

\* P value <0.05

Random effect: Individual (intercept) Variance: 0.5421 Standard deviation: 0.7363

328

330 The most tracked symptoms across all users were fatigue (99.5%), brain fog (88.3%), headaches 331 (85.1%) and muscle aches (78.6%) (appendix, p4). These symptoms were frequently co-reported 332 with each other and with the following symptoms: dizziness, nausea, muscle weakness, joint pain, 333 shortness of breath, palpitations, light sensitivity, noise sensitivity and memory issues (appendix, p5-334 6). Restricting the analysis to the first three cycles enabled us to conduct Pearson's chi-squared tests 335 as there were equal numbers of cycles for each user, and in this analysis, 25/36 individual symptoms 336 differed significantly between menstrual cycle phases (appendix, p7-9). However, this approach may 337 overlook long-term trends and variations in symptoms over time so we also built individual regression 338 models for each symptom (appendix, p10-21). In this analysis 32/36 symptoms showed a significant 339 association between symptom severity and menstrual cycle phase, with 22 of these being worse in

the menstrual phase and better in the luteal phase (appendix, p10-21).

Approximately 85% of those affected by long COVID experience episodic symptoms that can rapidly fluctuate from periods of symptom stability to severe exacerbations, resulting in significant functional

fluctuate from periods of symptom stability to severe exacerbations, resulting in significant functional
 declines.<sup>3</sup> These periods of severe worsening symptoms are often called "crashes" by those living

at the second second second we second we second a second s

344 with complex chronic illnesses,<sup>35</sup> who may choose, where possible, to avoid scheduling strenuous

345 activities at times when they are more vulnerable to a crash. The frequency of crashes was higher

during menses, compared to all other phases, particularly the early luteal phase (p = 0.0002680)
 (appendix, p22). The mean percentage of days with crash was highest in the menstrual phase and

348 decreased over the cycle, plateauing between the early luteal and premenstrual phases (**Figure 2H**).

Adjusting for contraception type, disease type, age category, gravidity and time since joining the app

350 using a mixed-effects logistic regression model, crashes remained less frequent in every phase

351 compared to menstruation (**Table 3**). The late luteal phase showed the greatest reduction in crashes

352 (odds ratio (OR)=0.888, p=5.87E-05) compared to the menstrual phase. The follicular, early luteal

and premenstrual phase also showed significant reductions (OR=0.947, p=0.0367 and OR=0.900,

354 p=0.000109 and OR=0.919, p=0.0333, respectively).

355 Crashes were significantly less frequent in users on combined hormonal contraception (OR=0.548,

356 p=0.0409), compared to users not on hormonal contraception. Users on progestin-only contraception

also had fewer crashes compared to users not on hormonal contraception but this was not

358 significantly different (OR=0.864, p=0.446). In comparison to those with long COVID, users with

359 ME/CFS had significantly more crashes (OR=1·47, p=0·00291) and users with both long COVID and

360 ME/CFS had higher odds of crash (OR=1.85, p=4.4E-05). Age and gravidity were not significantly

associated with crashes.

# 363

# Table 3. The fitting result of binomial regression model (crashes)

Fixed effects	Odds ratio (OR)	95% CI (lower)	95% CI (upper)	P value
Menstrual phase	<u> </u>	<b>X X</b>		
Menses	-	-	-	-
Follicular	0.947	0.900	0.997	0.0367*
Early luteal	0.900	0.853	0.949	0.000109
Late luteal	0.888	0.838	0.941	5·87E-05*
Premenstrual	0·919	0.851	0.993	0.0333*
Hormonal contraception type				
None	-	-	-	-
Oestrogen & progestin	0.548	0.350	0.856	0.00822*
Progestin only	0.864	0.593	1.260	0.446
Disease type				
Long COVID only	-	-	-	-
ME/CFS only	1.47	1.14	1.89	0.00291*
Long COVID and ME/CFS	1.85	1.38	2.48	4·4E-05*
Age category				
< 30	-	-	-	-
30-39	0.752	0.549	1.03	0.0761
>= 40	0.799	0.564	1.13	0.209
Gravidity				
Multigravida	-	-	-	-
Nulligravida	1.00	0.768	1.30	0.998
Quarters post-joining				
1	-	-	-	-
2	0.943	0.894	0.994	0.0304*
3	0.937	0.881	0.997	0.0396*
4	1.10	1.02	1.18	0.00916*
5	0.979	0.903	1.06	0.598
6	1.09	0.851	1.40	0.495

\* P value <0.05

Random effect: Individual (intercept) Variance: 0.5414 Standard deviation: 0.7358

### 366 Discussion

- 367 This study is the first to describe changes to long COVID and ME/CFS symptoms across the
- 368 menstrual cycle, using prospectively collected app data. In line with previous reports, overall symptom
- 369 scores and crash incidence varied by disease, with the lowest scores reported in individuals with long
- 370 COVID, higher scores in individuals with ME/CFS and the highest scores in individuals with both.<sup>7</sup> The
- 371 most tracked symptoms and clustering are broadly in line with Davis *et al.* 2021 who found that
- 372 fatigue and brain fog were the most frequent symptoms in long COVID patients after 6 months of the
- 373 study, alongside post-exertional malaise/crashes<sup>3</sup>.
- When daily symptom ratings were summed to form an overall symptom score, there were small but
- 375 significant changes between phases: symptoms were most severe in the menstrual and premenstrual
- 376 phases and least severe in the early luteal phase. We saw a similar pattern with crash incidence, and
- these findings are in line with our hypothesis and with previous findings <sup>3,17</sup>. When disease type, age,
- 378 reproductive history and contraception type were adjusted for, the menstrual cycle phase still had a
- 379 small, but significant impact on symptom score and crashes. Use of combined hormonal
- 380 contraception was associated with significantly ameliorated symptoms and a reduced risk of crashes.
- 381 This warrants further investigation as combined hormonal contraception is generally considered safe,
- 382 cheap and is already widely available making it a promising approach to ameliorate long COVID
- and ME/CFS symptoms.
- The major strength of this study is its use of data prospectively collected from a large cohort of users of the Visible app. Users enter data in real time as part of their personal healthcare routines, reducing
- 386 recall and recruitment bias. The availability of a large volume of data enabled us to examine changes
- 387 over the menstrual cycle in granular detail, since sufficient user-days were assigned to even the
- 388 shortest phase (premenstrual) for statistical analysis. The comprehensive list of 36 symptoms tracked
- allows a thorough investigation into the effect of menstrual cycle phase on long COVID and ME/CFS.
- 390 The use of 4-point Likert scales for symptom severity ensured consistency in data reporting and
- analysis. This approach also allowed us to calculate an 'overall symptom score' as a single
- comprehensive indicator of a user's health on any given day. We also examined individual symptoms
- 393 and crashes to provide a more detailed picture of symptom severity.
- 394 The use of app data also carries some limitations. Our data is a convenience sample. Individuals with 395 limited access to technology or digital literacy are unlikely to be app users, and individuals who choose 396 to use the app and participate in the study might also have different characteristics or health behaviours 397 compared to those who do not, potentially limiting the applicability of the results. Importantly, our study 398 also relies on self-reported disease status, which may introduce inaccuracies into disease group 399 assignments, and daily symptoms, which may introduce biases such as over-reporting or under-400 reporting of symptoms, and inaccuracies in tracking. Different users might also interpret and rate 401 symptoms differently. However, to address this issue, we included 'individual' as a random effect in the 402 model. The userbase of the app also means that there are no healthy controls, which prevents us from 403 determining whether changes in long COVID and ME/CFS symptoms are due to the ovarian hormones

404 affecting the disease, or whether the observed change in symptoms reflects normal variation in 405 wellbeing across the menstrual cycle. However, our finding that combined hormonal contraception is 406 associated with lower symptom scores, does support the hypothesis that ovarian hormones directly 407 affect disease symptoms.

408 While our model adjusts for several variables, there may still be unmeasured confounders. Within-409 individual analysis means that the association between symptom severity and menstrual cycle phase 410 is likely to be robust to this, but this could certainly affect the relationship between contraceptive use 411 and symptoms. Furthermore, the demographic survey questions were completed when the user first 412 enrolled and were not updated over the study. Therefore, any changes in contraception use during the 413 study would not have been captured. To minimise the cognitive burden of participation on app users, 414 we designed the survey to be as short as possible, but this meant we did not collect information on 415 other geographic location, ethnicity, socioeconomic status, body-mass index, education or other health 416 conditions including gynaecological disorders. Nor were we able capture daily contraception 417 information, including emergency contraception use, or any other hormonal intake (e.g. testosterone or 418 hormone replacement therapy (HRT)).

419 The results presented here support the idea that menstrual cycle phase influences long COVID and 420 ME/CFS symptoms. Broadly, people living with long COVID or ME/CFS may notice that their symptoms 421 are worse during the perimenstrual period and better in the early luteal phase. The knowledge that they 422 are more likely to crash during menstruation could improve guality of life, by allowing them to schedule 423 strenuous activities, which might cause a crash and cannot be carried out during a crash, for other 424 phases of the menstrual cycle. Furthermore, the association between combined hormonal 425 contraceptives, lower symptom scores and fewer crashes points towards a role for ovarian hormones 426 in modulating symptoms and highlights the therapeutic potential of oestrogen-containing contraceptives 427 in long COVID and ME/CFS.

# 429 Declarations

- 430 Funding AG is funded by the UK Medical Research Council (MRC) [grant number MR/W00710X/1].
- 431 CM acknowledges funding from the MRC Centre for Global Infectious Disease Analysis
- 432 (MR/X020258/1), the NIHR (NIHR200908); a philanthropic donation from Community Jameel
- 433 supporting the work of the Jameel Institute; The Eric and Wendy Schmidt Fund (G-22-63345). JTH
- 434 acknowledges funding from the Bill & Melinda Gates Foundation (INV-005289). VM acknowledges
- 435 funding from Borne, Action Medical Research (GN2971), the UK Medical Research Council
- 436 (MR/X006875/1) and Genesis Research Trust. The funders of the study had no role in the study
- 437 design, data collection, data analysis, data interpretation, or writing of the report. For the purpose of
- 438 open access, the author has applied a 'Creative Commons Attribution' (CC BY) licence to any Author
- 439 Accepted Manuscript version arising from this submission.
- 440
- 441 Availability of data and materials While all data used in this analysis were anonymised, the
- 442 individual-level nature of the data used risks individuals being identified or being able to self-identify if
- it is released publicly. However, the app data can be requested by bona fide researchers for specified
- 444 scientific purposes by emailing info@makevisible.com.
- 445

# 446 **Code availability**

- 447 <u>https://github.com/AbiGoodship/effect\_of\_ovarian\_hormones\_on\_long\_COVID\_and\_ME\_symptoms</u>
- 448

Competing interests. During the course of the study HL was employed by, and RP was a paid contractor for Visible Health Inc., the company that owns and operates the Visible app. Some of the study participants had paid for access to certain Visible features, though not access to symptom tracking or menstrual cycle tracking functionality which is free for all Visible app users. This was a study across both the free and paid user base. All other authors declare no competing interests.

454

455 Authors' Contributions VM and CM conceptualised the study. RP and HL curated the data. JH, AG

- and CM developed the methodology. AG formally analysed and visualised the data. CM and VM
- 457 supervised the study. AG wrote the original manuscript draft. All authors were responsible for the
- 458 methodology and review and editing of the manuscript. All authors discussed, edited, and approved
- the final version of the manuscript. All authors had final responsibility for the decision to submit the
- 460 manuscript for publication.
- 461

medRxiv preprint doi: https://doi.org/10.1101/2025.01.24.25321092; this version posted January 27, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

#### 462 References

463 1 Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and 464 recommendations. Nat Rev Microbiol. 2023; 21. DOI:10.1038/s41579-022-00846-2. 465 2 Self-reported coronavirus (COVID-19) infections and associated symptoms, England and 466 Scotland - Office for National Statistics. 467 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddis 468 eases/articles/selfreportedcoronaviruscovid19infectionsandassociatedsymptomsenglandandsc 469 otland/november2023tomarch2024#long-covid (accessed July 22, 2024). 470 Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 3 471 7 months of symptoms and their impact. EClinicalMedicine 2021; 38. 472 DOI:10.1016/j.eclinm.2021.101019. 473 Carlile O, Briggs A, Henderson AD, et al. Impact of long COVID on health-related quality-of-4 474 life: an OpenSAFELY population cohort study using patient-reported outcome measures 475 (OpenPROMPT). The Lancet Regional Health - Europe 2024; 40: 100908. 476 5 Wong TL, Weitzer DJ. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome 477 (ME/CFS)-A systemic review and comparison of clinical presentation and symptomatology. 478 Medicina (Lithuania) 2021; 57. DOI:10.3390/medicina57050418. 479 6 Sukocheva OA, Maksoud R, Beeraka NM, et al. Analysis of post COVID-19 condition and its 480 overlap with myalgic encephalomyelitis/chronic fatigue syndrome. J Adv Res. 2022; 40. 481 DOI:10.1016/j.jare.2021.11.013. 482 7 Haider S, Janowski AJ, Lesnak JB, et al. A comparison of pain, fatigue, and function between 483 post-COVID-19 condition, fibromyalgia, and chronic fatigue syndrome: a survey study. Pain 484 2023; 164: 385-401. 485 8 Kedor C, Freitag H, Meyer-Arndt L, et al. A prospective observational study of post-COVID-19 486 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers 487 associated with symptom severity. Nature Communications 2022 13:1 2022; 13: 1-13. 488 9 Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic Fatigue Syndrome After Infectious 489 Mononucleosis in Adolescents. Pediatrics 2009; 124: 189-93. 490 10 Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes 491 precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 2006; 333: 575. Valdez AR, Hancock EE, Adebayo S, et al. Estimating prevalence, demographics, and costs of 492 11 493 ME/CFS using large scale medical claims data and machine learning. Front Pediatr 2019; 6: 494 433309. 495 12 Vahratian A, Lin J-MS, Bertolli J, Unger ER. Myalgic Encephalomyelitis/Chronic Fatigue 496 Syndrome in Adults: United States, 2021-2022. 2023; published online Dec 13. 497 DOI:10.15620/CDC:134504. 498 13 Samms GL, Ponting CP. Unequal access to diagnosis of myalgic encephalomyelitis in 499 England. medRxiv 2024; : 2024.01.31.24302070. 500 14 Pendergrast T, Brown A, Sunnquist M, et al. Housebound versus nonhousebound patients with 501 myalgic encephalomyelitis and chronic fatigue syndrome. Chronic Illn 2016; 12: 292–307. 502 15 Smith K. Women's health research lacks funding — these charts show how. Nature 2023; 617. 503 DOI:10.1038/d41586-023-01475-2. 504 Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG. Systematic review and meta-analysis of 16 505 the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl 506 Med 2020; 18. DOI:10.1186/S12967-020-02269-0. 17 Sigfrid L, Drake TM, Pauley E, et al. Long Covid in adults discharged from UK hospitals after 507 508 Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical 509 Characterisation Protocol. The Lancet Regional Health - Europe 2021; 8. 510 DOI:10.1016/j.lanepe.2021.100186. 511 Sund M, Fonseca-Rodríguez O, Josefsson A, Welen K, Fors Connolly AM. Association 18 512 between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and 513 death due to COVID-19: A cohort study. BMJ Open 2022; 12. DOI:10.1136/bmjopen-2021-514 053032. 515 19 Costeira R, Lee KA, Murray B, et al. Estrogen and COVID-19 symptoms: Associations in 516 women from the COVID Symptom Study. PLoS One 2021; 16. DOI:10.1371/journal.pone.0257051. 517 518 20 Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long 519 COVID. Nat Rev Immunol. 2023; 23. DOI:10.1038/s41577-023-00904-7. 520 21 Hoffmann JP, Liu JA, Seddu K, Klein SL. Sex hormone signaling and regulation of immune function. Immunity. 2023; 56. DOI:10.1016/j.immuni.2023.10.008. 521

- 522 22 Alvergne A, Högqvist Tabor V. Is Female Health Cyclical? Evolutionary Perspectives on 523 Menstruation. Trends Ecol Evol. 2018; **33**. DOI:10.1016/j.tree.2018.03.006.
- Kempe P, Hammar M, Brynhildsen J. Symptoms of multiple sclerosis during use of combined hormonal contraception. *European Journal of Obstetrics and Gynecology and Reproductive Biology* 2015; **193**. DOI:10.1016/j.ejogrb.2015.06.030.
- 52724Newson L, Lewis R, O'Hara M. Long Covid and menopause the important role of hormones528in Long Covid must be considered. *Maturitas* 2021; **152**. DOI:10.1016/j.maturitas.2021.08.026.
- 529 25 Milne-Ives M, Van Velthoven MH, Meinert E. Mobile apps for real-world evidence in health
  530 care. Journal of the American Medical Informatics Association. 2020; 27.
  531 DOI:10.1093/jamia/ocaa036.
- 532 26 Visible Activity tracking for Long Covid and ME/CFS. https://www.makevisible.com/ 533 (accessed Aug 2, 2024).
- 534 27 Posit team. RStudio: Integrated Development Environment for R. 2024.
- Munro MG, Critchley HOD, Fraser IS, *et al.* The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. *International Journal of Gynecology and Obstetrics* 2018; 538
  143. DOI:10.1002/ijgo.12666.
- 539 29 Reed BG, Carr BR. The Normal Menstrual Cycle and the Control of Ovulation. 2000.
- Wurz A, Culos-Reed SN, Franklin K, DeMars J, Wrightson JG, Twomey R. 'I feel like my body
  is broken': exploring the experiences of people living with long COVID. *Quality of Life Research* 2022; **31**. DOI:10.1007/s11136-022-03176-1.
- 543 31 Schmalenberger KM, Tauseef HA, Barone JC, *et al.* How to study the menstrual cycle:
  544 Practical tools and recommendations. Psychoneuroendocrinology. 2021; **123**.
  545 DOI:10.1016/j.psyneuen.2020.104895.
- 546 32 Wei SM, Schiller CE, Schmidt PJ, Rubinow DR. The role of ovarian steroids in affective 547 disorders. Curr Opin Behav Sci. 2018; **23**. DOI:10.1016/j.cobeha.2018.04.013.
- 548 33 Gehlert S, Song IH, Chang CH, Hartlage SA. The prevalence of premenstrual dysphoric
  549 disorder in a randomly selected group of urban and rural women. *Psychol Med* 2009; 39.
  550 DOI:10.1017/S003329170800322X.
- 55134Scientific Image and Illustration Software | BioRender. https://www.biorender.com/ (accessed552Aug 8, 2024).
- 55335O'Brien KK, Brown DA, McDuff K, et al. Conceptualising the episodic nature of disability554among adults living with Long COVID: a qualitative study. BMJ Glob Health 2023; 8.555DOI:10.1136/BMJGH-2022-011276.
- 556